The United States is facing a significant challenge when it comes to drug patent evergreening, a practice that extends patent rights on specific products to block generic and biosimilar competition. This issue has caught the attention of both the Federal Trade Commission (FTC) and Congress, who are now taking steps to address it.
The American patent system for pharmaceuticals is designed to incentivize innovation by allowing drug companies to sell new medications exclusively for a period of time before generics or biosimilars can enter the market. However, companies have found ways to extend their patent protection by filing secondary patents that cover aspects like dosages, formulations, and delivery mechanisms. This practice can grant them an additional three years of monopoly protection, leading to higher drug prices for consumers.
Recent studies have shown a significant increase in the number of patents filed by drug companies, many of which involve minor changes to existing drugs. While some of these changes can benefit patients, such as improving adherence and persistence, others are seen as abuses of the patent system. For example, companies have been known to file patents for insignificant items like a plastic strap attached to an inhaler, which has no direct impact on the drug itself.
The issue extends beyond inhalers, with nearly three-quarters of new drug patents issued between 2005 and 2015 being for pharmaceuticals already on the market. This practice has raised concerns about the hindrance of competition and the resulting impact on healthcare spending.
One area of particular focus for the FTC is biosimilars, which have the potential to significantly reduce healthcare costs. However, patent thickets, which create hurdles for generic and biosimilar competitors, have impeded their uptake. Bipartisan efforts are underway in Congress to address these issues, with multiple bills aimed at closing loopholes in the patent system.
Experts and policymakers are advocating for reforms that strike a balance between rewarding innovation and promoting competition to make prescription drugs more affordable. The Affordable Prescriptions for Patients Act, for example, seeks to limit patent thickets and product hopping, giving the FTC authority to enforce limits on patent litigation.
While the pharmaceutical industry defends its intellectual property rights, there is growing consensus that patent reform is necessary. The FTC has taken steps to challenge drug makers on improperly listed patents, but the effectiveness of these actions remains to be seen.
In conclusion, pressure is mounting for changes to the pharmaceutical patent system, and it remains to be seen how quickly these reforms will be implemented. With bipartisan support and regulatory scrutiny, the hope is that these efforts will lead to a more competitive and affordable drug market for consumers.
